Corneal Degeneration, Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Conditions
Brief summary
Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Collagen Cross-linking in Eyes With Corneal Thinning Conditions
Detailed description
Patients with progressive keratoconus, pellucid marginal degeneration, or at risk for post-refractive corneal ectasia will be recruited and undergo epithelial-on corneal crosslinking with the Peschke PXL-330 system using pulsed, accelerated energy delivery. Patients will undergo monitoring for 1 year, with serial measurements of corneal topography, visual acuity, pachymetry, and visual function.
Interventions
COMBINATION_PRODUCTPXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Sponsors
Cornea Associates of Texas
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 8 years of age or older * Signed written informed consent * Willingness and ability to comply with schedule for follow-up visits * Contact Lens Wearers Only: * Removal of contact lenses (if applicable) for the required period of time prior to the screening refraction: Soft, discontinue 3 days; Soft Extended Wear, discontinue 3 days; Soft Toric, discontinue 3 days; Rigid gas permeable, discontinue 2 Weeks (subjects who cannot function without wearing their contact lenses, may forgo discontinuation of contact lenses) And one or more of the following: * Presence of central or inferior steepening. * Axial topography consistent with keratoconus, post-surgical ectasia, or pellucid marginal degeneration * Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as: Fleischer ring, Vogt's striae, Decentered corneal apex, Munson's sign, Rizzutti's sign, Apical Corneal scarring consistent with Bowman's breaks, Scissoring of the retinoscopic reflex, Crab-claw appearance on topography * Steepest keratometry (Kmax) value ≥ 47.20 D * I-S keratometry difference \> 1.5 D on the Pentacam/Orbscan map or topography map * Posterior corneal elevation \>16 microns * Thinnest corneal point \>300 microns
Exclusion criteria
* Eyes classified as either normal or atypical normal on the severity grading scheme. * Corneal thickness \< 300 microns measured by ultrasonic pachymetry or pentacam. * Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications, for example: History of or active corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, etc.) Clinically significant corneal scarring in the CXL treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure. * Pregnancy (including plan to become pregnant) or lactation during the course of the study * A known sensitivity to study medications * Patients with nystagmus or any other condition that would prevent a steady gaze during the CXL treatment or other diagnostic tests. * Patients with a current condition that, in the physician's opinion, would interfere with or prolong epithelial healing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| K-Max | 12 Months | Change in K-Max measured by corneal topography, compared to baseline |
| K-Mean | 12 Months | Change in K-Mean measured by corneal topography, compared to baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Uncorrected Visual Acuity | 12 Months | Change in uncorrected corrected visual acuity using snellen measurements, compared to baseline |
| Best Corrected Visual Acuity | 12 Months | Change in best corrected visual acuity using snellen measurements, compared to baseline |
| Central Pachymetry | 12 Months | Change in central pachymetry, measured by Pentacam compared to baseline |
Countries
United States
Outcome results
None listed